EBS vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 16, 2026

EBS

46.5
AI Score
VS
PCRX Wins

PCRX

48.7
AI Score

Investment Advisor Scores

EBS

47score
Recommendation
HOLD

PCRX

49score
Recommendation
HOLD

Detailed Metrics Comparison

Metric EBS PCRX Winner
Forward P/E 5.5 10.5 EBS
PEG Ratio 0.38 0.99 EBS
Revenue Growth -52.4% -1.6% PCRX
Earnings Growth -93.8% 483.3% PCRX
Tradestie Score 46.5/100 48.7/100 PCRX
Profit Margin -40.2% 5.1% PCRX
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

EBS 1M: -19.4% · 3M: +28.7% PCRX 1M: +0.4% · 3M: +56.9%

Current Technical Phase

EBS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 38.4 · Price: $5.79

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.4% over 20 days), RSI 83

RSI (14): 82.6 · Price: $36.46

Fundamentals Snapshot

Metric EBS PCRX
Market Cap — —
Forward P/E 5.5 10.5
Trailing P/E — 39.2
Revenue (TTM) — —
Revenue Growth -52.4% -1.6%
Gross Margin 43.4% 78.0%
Operating Margin 5.8% 4.1%
EPS -5.00 0.93
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate with a higher AI composite score (48.7/100 vs. 46.5/100), supported by its current technical phase (EBS: Neutral, PCRX: Markup) and fundamental profile.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.